Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

SOHO 2020 | Next questions for mantle cell lymphoma

Jonathon Cohen • 9 Sep 2020
SOHO 2020
Lymphoma Mantle Cell Lymphoma CAR-T

Jonathon B. Cohen, MD, MS, of Winship Cancer Institute of Emory University, Atlanta, GA, outlines the next questions in mantle cell lymphoma, including a greater understanding of the requirement of frontline therapies, the management of disease using minimal residual measurements, as well as identifying patients appropriate for CAR T-cell therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jonathon Cohen

Immunotherapeutic approaches for MCL patients who progress following BTKi treatment 0:57
Immunotherapeutic approaches for MCL patients who progress following BTKi treatment
Jonathon Cohen • 11 Dec 2023
Outcomes of patients with MCL who require urgent treatment at time of diagnosis 0:49
Outcomes of patients with MCL who require urgent treatment at time of diagnosis
Jonathon Cohen • 11 Dec 2023
A pooled analysis to determine the optimal Ki-67 index cut-off point for predicting outcomes in MCL 0:55
A pooled analysis to determine the optimal Ki-67 index cut-off point for predicting outcomes in MCL
Jonathon Cohen • 11 Dec 2023
Updated results of the BRUIN trial: pirtobrutinib in R/R MCL 0:55
Updated results of the BRUIN trial: pirtobrutinib in R/R MCL
Jonathon Cohen • 11 Dec 2023

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals